
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.
Publication
, Journal Article
Cannata, F; Chiarito, M; Reimers, B; Azzolini, E; Ferrante, G; My, I; Viggiani, G; Panico, C; Regazzoli, D; Ciccarelli, M; Voza, A; Aghemo, A ...
Published in: Eur Heart J Cardiovasc Pharmacother
November 1, 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Heart J Cardiovasc Pharmacother
DOI
EISSN
2055-6845
Publication Date
November 1, 2020
Volume
6
Issue
6
Start / End Page
412 / 414
Location
England
Related Subject Headings
- Treatment Outcome
- Risk Factors
- Registries
- Protective Factors
- Prospective Studies
- Pneumonia, Viral
- Pandemics
- Hypertension
- Humans
- Hospitalization
Citation
APA
Chicago
ICMJE
MLA
NLM
Cannata, F., Chiarito, M., Reimers, B., Azzolini, E., Ferrante, G., My, I., … Stefanini, G. G. (2020). Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother, 6(6), 412–414. https://doi.org/10.1093/ehjcvp/pvaa056
Cannata, Francesco, Mauro Chiarito, Bernhard Reimers, Elena Azzolini, Giuseppe Ferrante, Ilaria My, Giacomo Viggiani, et al. “Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.” Eur Heart J Cardiovasc Pharmacother 6, no. 6 (November 1, 2020): 412–14. https://doi.org/10.1093/ehjcvp/pvaa056.
Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412–4.
Cannata, Francesco, et al. “Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.” Eur Heart J Cardiovasc Pharmacother, vol. 6, no. 6, Nov. 2020, pp. 412–14. Pubmed, doi:10.1093/ehjcvp/pvaa056.
Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412–414.

Published In
Eur Heart J Cardiovasc Pharmacother
DOI
EISSN
2055-6845
Publication Date
November 1, 2020
Volume
6
Issue
6
Start / End Page
412 / 414
Location
England
Related Subject Headings
- Treatment Outcome
- Risk Factors
- Registries
- Protective Factors
- Prospective Studies
- Pneumonia, Viral
- Pandemics
- Hypertension
- Humans
- Hospitalization